Business
Immuron New U.S. Department of Defense Award & Clinical Trial Update
Highlights: New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and ShigellaUniformed Services University P2TD clinical study update MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Silver Spring, M
About this update from Immuron Limited
[{"type":"image","alt":"Immuron Limited","displaySize":"","headline":null,"caption":"Immuron Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":82,"url":"https://media.zenfs.com/en/globenewswire.com/9a84f6210d4cd66bdccdf48c09d55917"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LBQdBGezvMSw61jZdfyUdw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/9a84f6210d4cd66bdccdf48c09d55917","width":300,"height":82}},"lazy":false},{"type":"text","content":"Highlights:","length":11,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"New US Department of Defense award to develop two new oral therapeutics targeting Campylobacter and Shigella","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Uniformed Services University P2TD clinical study update ","length":56,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":164,"olType":false},{"type":"text","content":"MELBOURNE, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, announces a new research agreement with the Naval Medical Research Command (NMRC) and the Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, USA funded by a U.S. Department of Defense subaward.","length":378,"tagName":"p"},{"type":"text","content":"As previously announced on August 16, 2024, the Naval Medical Research Command and the Walter Reed Army Institute of Research, in collaboration with Immuron, are progressing the development of novel vaccines targeting Campylobacter jejuni and Shigella sonnei. Under a recently executed collaborative research agreement with the Henry M. Jackson Foundation, new vaccine preparations against these pathogens have been developed and formulated at the military research institutes and subsequently provided to Immuron. Utilizing its proprietary technology platform, Immuron will produce two hyper-immune bovine colostrum products for pre-clinical evaluation, with the objective of advancing a combined colostrum-based therapeutic specifically designed for the US military.","length":768,"tagName":"p"},{"type":"text","content":"The company also advises that the Uniformed Services University topline results from its clinical trial evaluating the effectiveness of enter...